Раннее сосудистое старение. Современное состояние проблемы (обзор)
Реферат
Атеросклероз является патогенетической основой развития кардиоваскулярных заболеваний. Все большее внимание уделяется изучению ранних стадий сосудистой патологии (артериосклероза), часто ассоциированной с артериальной гипертонией и ишемической болезнью сердца в молодом возрасте. В настоящее время развивается концепция синдрома раннего сосудистого старения (early vascular ageing, EVA). Изучаются его генетические аспекты, биология теломер, процессы системного воспаления, жесткости сосудистой стенки прямыми и косвенными методами. Этих моментов касаются и первые результаты наших исследований. До сих пор отсутствуют конкретные подходы к лечению EVA-синдрома, а рекомендации в основном сводятся к контролю факторов кардиоваскулярного риска. Развивающиеся подходы касаются создания новых антигипертензивных препаратов, вазопротекторов (селективные агонисты рецепторов к ангиотензину II второго типа), активаторов рецепторов NF-κВ, антидиабетических препаратов.
Тэги
1. Яхонтов Д.А., Коростелева Е.В. Особенности течения и приверженности к лечению при различных вариантах стабильной стенокардии в сочетании с артериальной гипертензией у жителей г. Новосибирска // Компл. пробл. сердечно-сосудистых заболеваний. 2014. (4). 13–18.
2. Anderson K.M., Wilson P.W., Odell P.M., Kannel W.B. An updated coronary risk profile. A statement for health professionals // Circulation. 1991. (83). 356–362.
3. Ben-Shlomo Y., Spears M., Boustred C., May M., Anderson S.G., Benjamin E.J. et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects // J. Am. Coll. Cardiol. 2013. (63). 636–646.
4. Bilo G., Giglio A., Styczkiewicz K., Caldara G., Maronati A., Kawecka-Jaszcz K. et al. A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall // J. Hypertens. 2007. (25). 2058–2066.
5. Boggia J., Li Y., Thijs L., Hansen T.W., Kikuya M., Bjo¨rklund-Bodegard K. et al. International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study // Lancet. 2007. (370) 1219–1229.
6. Briet M., Pierre B., Laurent S., London G.M. Arterial stiffness and pulse pressure in CKD and ESRD // Kidney Int. 2012. (82). 388–400.
7. Burgess S., Butterworth A., Malarstig A., Thompson S.G. Use of Mendelian randomisation to assess potential benefit of clinical intervention // BMJ. 2012. (345). е7325.
8. Cawthon R.M. Telomere length measurement by a novel monochrome multiplex quantitative PCR method // Nucleic Acids Res. 2009. (37). е21.
9. Cecelja M., Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review // Hypertension. 2009. (54). 1328–1336.
10. Chirinos J.A., Segers P. Noninvasive evaluation of left ventricular afterload: part 2: arterial pressure-flow and pressure-volume relations in humans // Hypertension. 2010. (56). 563–570.
11. Chirinos J., Segers P., Gillebert T.C., Gupta A.K., De Buyzere M.L., De Bacquer D. et al. on behalf of the Asklepios Investigators. Arterial properties as determinants of time-varying myocardial stress in humans // Hypertension. 2012. (60). 64–70.
12. Codd V. et al. Identification of seven loci affecting mean telomere length and their association with disease // Nat. Genet. 2013. (45). 422–427.
13. Denil S.L., Rietzschel E.R., De Buyzere M.L., Van Daele C.M., Segers P., De Bacquer D. et al. Asklepios Investigators. On cross-sectional associations of leukocyte telomere length with cardiac systolic, diastolic and vascular function: the Asklepios study // PLoS One. 2014. 9. e115071.
14. D’Agostino R.B., Sr., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study // Circulation. 2008. (117). 743–753.
15. Di Rienzo M., Grassi G., Pedotti A., Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24h average blood pressure // Hypertension. 1983. (5). 264–269.
16. Eichler K., Puhan M.A., Steurer J., Bachmann L.M. Prediction of first coronary events with the Framingham score: a systematic review // Am. Heart J. 2007. (153) 722–731.
17. Fonseca V.A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus // Am. J. Cardiol. 2011. (108). 52–58.
18. Gluckman P.D., Hanson M.A., Cooper C., Thornburg K.L. Effect of in utero and early-life conditions on adult health and disease // N. Engl. J. Med. 2008. (359). 61–73.
19. Gottsäter M., Östling G., Persson M., Engström G., Melander O., Nilsson P.M. Non-hemodynamic predictors of arterial stiffness after 17 years of follow-up: The Malmö Diet and Cancer study // J. Hypertens. 2015. (33). 957–965.
20. Haycock P.C. et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis // BMJ. 2014. (349). g4227.
21. Johansen N.B., Vistisen D., Brunner E.J. et al. Determinants of aortic stiffness: 16-year follow-up of the Whitehall II study // PLoS One. 2012. 7(5). e37165.
22. Kokkinos P., Myers J., Doumas M., Faselis C., Manolis A., Pittaras A. et al. Exercise capacity and all-cause mortality in prehypertensive men // Am J. Hypertens. 2009. (22). 735–741.
23. Lacolley P., Bezie Y., Girerd X., Challande P., Benetos A., Boutouyrie P. et al. Aortic distensibility and structural changes in sino-aortic denervated rats // Hypertension. 1995. (26). 337–340.
24. Lacolley P., Glaser E., Challande P., Boutouyrie P., Mignot J.P., Duriez M. et al. Structural changes and in situ aortic pressure-diameter relationship in longterm chemical-sympathectomized rats // Am J. Physiol. 1995. (269). 407–416.
25. Laurent S., Briet M., Boutouyrie P. Arterial stiffness as surrogate end point: needed clinical trials. Hypertension. 2012. (60). 518–522.
26. Laurent S., Schlaich M., Esler M. New drugs, procedures, and devices for hypertension // Lancet. 2012. (380). 591–600.
27. Logan J.G., Engler M.B., Kim H. Genetic Determinants of Arterial Stiffness // J. Cardiovasc Transl. Res. 2015. 8. 23–43.
28. Mancia G., Parati G., Hennig M., Flatau B., Omboni S., Glavina F. et al. ELSA Investigators. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) // J. Hypertens. 2001. (19). 1981–1989.
29. Mancia G., Facchetti R., Parati G., Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment // J. Hypertens. 2012. (30). 1241–1251.
30. Mena L., Pintos S., Queipo N.V., Aizpu’rua J.A., Maestre G., Sulbara’n T. A reliable index for the prognostic significance of blood pressure variability // J. Hypertens. 2005. (23). 505–511.
31. National Institute of Health. Weight loss does not lower heart disease risk from type 2 diabetes (press release). NIH News, 19th October 2012.
32. Ndip A., Wilkinson F.L., Jude E.B., Boulton A.J., Alexander M.Y. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy // Diabetologia. 2014. (57). 2251–2260.
33. Nilsson P.M., Boutouyrie P., Laurent S. Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention // Hypertension. 2009. (54). 3–10.
34. Nilsson P.M., Boutouyrie P., Cunha P., Kotsis V., Narkiewicz K., Parati G. et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention // J. Hypertens. 2013. (8) .1517–1526.
35. Nilsson E.D., Elmståhl S., Minthon L., Nilsson P.M., Pihlsgård M., Tufvesson E., Nägga K. Nonlinear association between pulse wave velocity and cognitive function: a population-based study // J. Hypertens. 2014. (32). 2152–2157.
36. Ong K.T., Delerme S., Pannier B., Safar M.E., Benetos A., Laurent S., Boutouyrie P. Investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients // J. Hypertens. 2011. (29). 1034–1042.
37. O’Rourke M.F., Safar M.E., Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature // Vasc. Med. 2010. (15). 461–468.
38. Paoletti R., Bolego C., Poli A., Cignarella A. Metabolic syndrome, inflammation and atherosclerosis // Vasc. Health Risk Manag. 2006. (2). 145–152.
39. Palatini P., Casiglia E., Ga˛sowski J., Głuszek J., Jankowski P., Narkiewicz K. et al. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension // Vasc Health Risk Manag. 2011. (7). 725–739.
40. Parati G., Faini A., Valentini M. Blood pressure variability: its measurement and significance in hypertension // Curr. Hypertens. Rep. 2006. (8). 199–204.
41. Parati G., Vrijens B., Vincze G. Analysis and interpretation of 24-h blood pressure profiles: appropriate mathematical models may yield deeper understanding // Am. J. Hypertens. 2008. (21). 123–125.
42. Paulis L., Becker S.T., Lucht K., Schwengel K., Slavic S., Kaschina E., Thöne-Reineke C., Dahlöf B., Baulmann J., Unger T., Steckelings U.M. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling // Hypertension. 2012. (59). 485–492.
43. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M. et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts // Eur. Heart J. 2012. (33). 1635–1701.
44. Révész D., Milaneschi Y., Verhoeven J.E., Penninx B.W. Telomere length as a marker of cellular ageing is associated with prevalence and progression of metabolic syndrome // J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/ jc.2014–1851.
45. Redfield M.M., Jacobsen S.J., Borlaug B.A., Rodeheffer R.J., Kass D.A. Ageand gender-related ventricular-vascular stiffening: a communitybased study // Circulation. 2005. (112). 2254–2262.
46. Rothwell P.M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension // Lancet. 2010. (375). 938–948.
47. Scuteri A., Cunha P.G., Rosei E.A. et al. Arterial stiffness and influences of the metabolic syndrome: A cross-countries study // Atherosclerosis. 2014. (233). 654–660.
48. Seals D. R., Walker A.E., Pierce G.L., Lesniewski L.A. Habitual exercise and vascular ageing // J. Physiol. 2009. (587). 5541–5549.
49. Sharman J.E., Marwick T.H., Abhayaratna W.P., Stowasser M. Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing managEment of hypertension: the BP GUIDE study // Am. Heart J. 2012. (163). 761–767.
50. Staessen J.A., Thijs L., Fagard R., O’Brien E.T., Clement D., de Leeuw P.W. et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators // JAMA. 1999. (282). 539–546.
51. Stehouwer C.D., Henry R.M., Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease // Diabetologia. 2008. (51). 527–539.
52. Steckelings U.M., Paulis L., Namsolleck P., Unger T. AT2 receptor agonists: hypertension and beyond // Curr. Opin. Nephrol. Hypertens. 2012. (21). 142–146.
53. Thomsen T.F., McGee D., Davidsen M., Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study // Int. J. Epidemiol. 2002. (31). 817–822.
54. Tzanetakou I.P., Nzietchueng R., Perrea D.N., Benetos A. Telomeres and their role in aging and longevity // Curr. Vasc. Pharmacol. 2014. (12). 726–734.
55. Yasmin, Mc Eniery C.M., Wallace S. et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness // Authorinformation Erratumin Arterioscler. Thromb. Vasc. Biol. 2005. (25). 372–378.
56. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome // Cardiovasc. Res. 2006. 69 (3). 636–645
Нилсон П.М. – проф., e-mail: peter.nilsson@med.lu.se
Яхонтов Д.А. – д.м.н., проф. кафедры фармакологии, клинической фармакологии и доказательной медицины, e-mail: mich99@mail.ru
Останина Ю.О. – аспирант кафедры терапии, гематологии и трансфузиологии ФПК и ППВ, e-mail: Julia679@yandex.ru
